Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection

Expert Review of Anti-Infective Therapy

Volumn 13, Issue 10, 2015, Pages 1195-1212

  Park, Tae Eun ^a   Mohamed, Abdilahi ^a   Kalabalik, Julie ^a   Sharma, Roopali ^b  

^a FAIRLEIGH DICKINSON UNIVERSITY   (United States)

^b LONG ISLAND UNIVERSITY   (United States)

Author keywords

dolutegravir; elvitegravir; human immunodeficiency virus; integrase strand transfer inhibitor; raltegravir

Indexed keywords

ANTIRETROVIRUS AGENT; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; DOLUTEGRAVIR; ELVITEGRAVIR; INTEGRASE INHIBITOR; INTEGRASE STRAND TRANSFER INHIBITOR; RALTEGRAVIR; UNCLASSIFIED DRUG; INTEGRASE;

ACUTE PANCREATITIS; ANTIVIRAL RESISTANCE; ANXIETY DISORDER; BACKACHE; BRONCHITIS; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRESS SYNDROME; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TREATMENT FAILURE; FATIGUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LIVER DYSFUNCTION; MYALGIA; NAUSEA; NIGHTMARE; NONHUMAN; PRACTICE GUIDELINE; REVIEW; RHABDOMYOLYSIS; RHINOPHARYNGITIS; STEVENS JOHNSON SYNDROME; SUICIDAL IDEATION; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; HIV INFECTIONS; METABOLISM;

HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HUMANS;

EID: 84941744457     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2015.1075393     Document Type: Review

References (91)

1. Centers for disease control and prevention. estimated HIV incidence in the United States 2007-2010. HIV surveillance supplemental report. 2012. 17 4). Available from www.cdc.gov/hiv/pdf/statistics-hssr-vol-17-no-4.pdf [Last accessed 21 March 2015]
2. Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data-Uni ted States and 6 dependent areas-2011. HIV surveillance supplemental report. 2013. 18(5). Available from: www.cdc.gov/hiv/pdf/2011-monitoring-hiv-indicators-hssr-final. pdf [Last accessed 21 March 2015]
3. Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135(1):17-26
4. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. New Engl J Med 2011;365(6):493-505
5. Ray M, Logan R, Sterne JA, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010;24(1):123-37
6. Isentress-(raltegravir) [package insert]. Merck Sharp and Dohme, Corp; Whitehouse Stations, NJ: 2014
7. Vitekta-(elvitegravir) [package insert]. Gilead Sciences, Inc; Foster City, CA: 2014
8. StribildTM (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [package insert]. Gilead Sciences, Inc; Foster City, CA: 2012
9. Tivicay-(dolutegravir) [package insert]. ViiV Healthcare; Research Triangle Park, NC: 2014
10. Triumeq-(abacavir, dolutegravir, and lamivudine) [Package insert]. ViiV Healthcare; Research Triangle Park, NC: 2014
11. Markowitz M, Nguyen BY, Gotuz zo E, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48 week controlled study. J Acquir Immune Defic S yndr 2007;46(2):125-33
12. Gotuzzo E, Markowitz M, Ratanasuwan W, et al. Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HI V-1 infection: final results of a randomized, controlled, phase II study (Protocol 004). J Acquir Immune Defic Syndr 2012;61(1):73-7
13. Young B, Vanig T, Dejesus E, et al. A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-nave HIV-1-infected patients: 48 week results of the SHIELD trial. HIV Clin Trials 2010;11(5):260-9
14. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009;374(9692):796-806
15. Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-nave HIV-1-infected patients: final 5 year results from STARTMRK. J Acquir Immune Defic Syndr 2013;63(1):77-85.STARTMRK study led to the approval of raltegravir (RAL) in USA for the treatment of HIV infection in treatment-nave patients.
16. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359(4):339-54
17. Eron JJ, Cooper DA, Steigbigel RT, et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis 2013;13(7):587-96.BENCHMRK study led to the approval of RAL in USA for the tre atment of HIV infection in treatment-experienced patients.
18. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected pat ients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375(9712):396-407
19. Martinez E, Larrousse M, Libre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPRIAL study. AIDS 2010;24(11):1697-707
20. Gallien S, Braun J, Delaugerre C, et al. Efficacy and safety of ralte gravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. J Antimicrob Chemother 2011;66(9):2099-106
21. Reynes J , Trinh R, Pulido F, et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-nave subjects: 96 week results of the PROGRESS study. AIDS Res Hum Retroviruses 2013;29(2):256-65
22. Bedimo RJ, Drechsler H, Jain M, et al. The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-na ive patients. Impact on bone health. PLoS ONE 2014; 9(8):e106221
23. Raffi F,Babiker AG,Richert L,et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-nave adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial Lancet 2014 384 9958) 1942-51
24. Boyd MA, Kumarasamy N, Moore CL, et a l. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SEC OND-LINE): a randomised, open-label, non-inferiority study. Lancet 2013;381(9883):2091-9
25. Amin J, Boyd MA, Kumarasamy N, et al. Raltegravir non-inferior to nucleoside based regimens in SECOND-LINE thera py with lopinavir/ritonavir over 96 weeks: A randomised open label study for the treatment of HIV-1 infection. PLoS One 2015;10(2):e0118228
26. Gantner P, Koeppel C, Partisani M, et al. Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study. Scand J Infect Dis 2014;46(12):838-45
27. Monteiro P, Perez I, Laguno M, et al. Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study. J Antimicrob Chemother 2014;69(3):742-8
28. Harris M, Larsen G, Montan er JS. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS 2008;22(14):1890-2
29. Croce F, Vitello P, Dalla Pria A, et al. Severe raltegravir-Associated rhabdomyolysis: a case report and review of the literature. Int J STD AIDS 2010;21(11):783-5
30. Tsai WJ, Lee SS, Tsai HC, et al. Rapid onset of rhabdomyolysis after switching to a ral tegravir-based antiretroviral regimen. J Microbiol Immunol Infect 2013; pii:S1684-1182(13):00034-0
31. Isentress-(raltegravir) tablet. Detailed view: safety labeling changes approved by FDA enter for Drug Evaluation and Research (CDER). Available from: www.fda. gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm122184.htm [Last accessed 8 March 2015]
32. Zhang KS, Modi GM, Hsu S. DRESS syndrome associated with raltegravir. Dermatol Online J 2011;17(8):14
33. Loulergue P, Mir O. Raltegravir-induced DRESS syndrome. Scand J Infect Dis 2012; 44(10):802-3
34. Perry ME, Almaani N, Desai N, et al. Raltegravir-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: implications for clinical practice and patient safety. Int J STD AIDS 2013;24(8):639-42
35. Yee BE, Nguyen NH, Lee D. Extensive pulmonary involvement with raltegravir-induced DRESS syndrome in a postpartum woman with HIV. BMJ Case Rep 2014;2014
36. Calza L, Danese I, Colangeli V, et al. Skeletal muscle toxicity in HIV-1-infected patients treated with a raltegravir-containing antiretroviral therapy: a cohort study. AIDS Res Hum Retroviruses 2014;30(12): 1162-9
37. Lee FJ, Amin J, Bloch M, et al. Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults. J Acquir Immune Defic Syndr 2013;62(5):525-33
38. Madeddu G, De Socio GV, Ricci E, et al. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from the SCOLTA project long-term surveillance. Int J Antimicrob Agents 2015; 45(3):289-94
39. Hurt CB, Sebastian J, Hicks CB, Eron JJ. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United Sta tes, 2009-2012. Clin Infect Dis 2014;58(3):423-31
40. Hu Z, Kuritzkes DR. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J Acquir Immune Defic Syndr 2010;55(2):148-55
41. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379(9835):2429-38.GS-236-0103 study led to the approval of elvitegravir/cobicistat/ten ofovir disoproxil fumarate/emtricitabine in USA for the treatment of HIV infection in treatment-nave patients.
42. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir v ersus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379(9835):2439-48.GS-236-0102 study led to the approval of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine in USA for the treatment of HIV infection in treatment-nave patients.
43. Zolopa A, Sax PE, DeJesus E, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune D efic Syndr 2013;63(1): 96-100
44. Wohl DA,Cohen C,Gallant JE,et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-t ablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results J Acquir Immune Defic Syndr 2014 65, 3):e118-20
45. Rockstroh JK, DeJesus E, Henr y K, et al. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analys is of week 96 results. J Acquir Immune Defic Syndr 2013;62(5):483-6
46. Clumeck N, Molina JM, Henry K, et al. A randomized, double-blind comparison of single-tablet reg imen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr 2014;65(3):e1 21-4
47. Molina JM, Lamarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 2012;12(1):27-35
48. Elion R, Molina JM, Ramon Arribas Lopez J, et al. A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results. J Acquir Immune Defic Syndr 2013;63(4): 494-7
49. Arribas JR, Pialoux G, Gathe J, et al. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adu lts with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis 2014;14(7):581-9
50. Pozniak A, Markowitz M, Mills A, e t al. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGYNNRTI): 48 w eek results of a randomised, open-label, phase 3b non-inferiority trial. Lancet Infect Dis 2014;14(7):590-9
51. Mills A, Crofoot G, Ortiz R, et al. Switching from twice-daily raltegravir plus tenofovir dis oproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data. HIV Clin Trials 2014;15(2):51-6
52. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available from: www.aidsinfo.nih.gov/ContentFile s/AdultandAdolescentGL.pdf
53. Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014;312(4):410-25
54. Van Wesenbeeck L, Rondelez E, Feyaerts M, et al. Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treate d clinical isolates. Antimicrob Agents Chemother 2011;55(1):321-5
55. Abram ME, Hluhanich RM, Goodman DD, et al. Impact of primary elvitegravir resistance-Associated mutations in HIV-1 integrase on drug s usceptibility and viral replication fitness. Antimicrob Agents Chemother 2013;57(6):2654-63
56. Raffi F, Jaeger H, Quiros-Roldan E, et al. Once daily dolutegravir versus twice-daily raltegravir in antiretroviral-nave adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 2013;13:927-35.SPRING-2 study showed non-inferiority of dolutegravir (DTG) compared to RAL-based therapy in treatment-nave, HIV-infected patients.
57. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013;369(19):1807-18.SINGLE study demonstrated that DTG was superior to efavirenz/tenofovir disoproxil fumarate/emtricitabine in treatment-nave, HIV-infected patients.
58. Clotet B, Feinberg J, van L unzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-nave adults with HIV-1 infection (FLAMINGO): 48 week results from the randomized open-label 3b study. Lancet 2014; 383(9936):2222-31
59. Cahn P, Pozniak A, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-nave adults with HIV: week 48 results from the randomized double-blind, non-inferi ority SAILING study. Lancet 2013;382(9893):700-8.The efficacy of DTG in treatment-experienced, integrase strand transfer inhibitor-nave patients was demonstrated by the SAILING study that showed significantly greater viral load suppression with DTG compared to RAL group.
60. Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir-And/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis 2014;210(3):354-62
61. Akil B, Blick G, Hagins DP, et al. Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study. Antivir Ther 2015;20(3):343-8
62. Raffi F, Rachlis A, Brinson C, et al. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-nave HIV-infected individuals in three randomized trials. AIDS 2015;29(2):167-74
63. Patel DA, Snedecor SJ, Tang WY, et al. 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-nave HIV-1-infected patients: a systemic review and network meta-Analysis. PLoS One 2014;9(9): e105653
64. Raffi F, Rachlis A, Stellbrink H, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-nave adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferi ority SPRING-2 study. Lancet 2013;381(9868): 735-43
65. Curtis L,Nicholas G,Stainsby C,et al. Dolutegravir: clinical and laboratory safety in integrase inhibitor-nave patients. HIV Clin Trials 2014; 155)199-208
66. Thompson AB, Wynn BA, O Akerele D, et al. Acute pancreatitis associated with dolutegravir and lamivudine/abacavir administration. AIDS 2015;29(3):390-2
67. Mespléde T, Wainberg MA. Is resistance to dolutegravir possible when this drug is used in first-line therapy? Viruses 2014;6(9): 3377-85
68. Hightower KE, Wang R, Deanda F, et al. Dolutegravir (S/GS K1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 2011;55(10): 4552-9
69. DeAnda F, Hightower KE, Nolte RT, et al. Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics. PLoS ONE 2013;8(10):e77448
70. Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimirob Agents Chemother 2011;55(2):813-21
71. Underwood MR, Johns BA, Sato A, et al. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr 2012;61(3):297-301
72. Quashie P K, Mespléde T, Han YS, et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 2012;86(5):2696-705
73. Munir S, Thierry E, Malet I, et al. G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance. J Antimicrob Chemother 2015;70(3):739-49
74. Canducci F, Ceresola ER, Boeri E, et al. Cross-resistance profile of the novel integrase inhibitor dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis 2011;204(11):1811-15
75. Eron JJ, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week resu lts of the VIKING Study. J Infect Dis 2013;207(5):740-8
76. Cavalcanti Jde S, Ferreira JL, Guimarães PM, et al. High frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen. J Antimicrob Chemother 2015;70(3):926-9
77. Fourati S, Charpentier C, Amiel C, et al. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1 infected patients. J Antimicrob Chemother 2015; 70(5):1507-12
78. Hardy I, Brenner B, Quashie P, et al. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. J Antimicrob Chemother 2015; 70(2):405-11
79. Eron JJ Jr., Rockstroh JK, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 2011;11(12):907-15
80. European AIDS Clinical Society (EACS). Guidelines version 7.1. Available from: www.eacsociety.org/files/guidelines-7.1-english.pdf
81. Spreen W, Ford SL, Chen S, et al. GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-Acting injectable administration in healthy subjects. J Acquir Immune Defic Syndr 2014;67(5): 481-6
82. Sp reen W, Williams P, Margolis D, et al. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-Acting nanosuspensions in healthy adults. J Acquir Immune Defic Syndr 2014;67(5 ):487-92
83. Spreen W, Min S, Ford SL, et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials 2013;14(5):192-2 03
84. Margolis DA, Brinson CC, Smith GHR, et al. Cabotegravir and rilpivirine as two-drug oral maintenance therapy: LATTE week 96 results Poster number 554LB. Poster presented at Conference on Retroviruses and Opportunistic Infections (CROI); 23-26 February 2015; Seattle, Washington
85. Fenwick C, Amad M, Bailey MD, et al. Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor. Antimirob Agents Chemother 2014;58(6): 3233-44
86. Aslanyan S, Ballow CH, Sabo JP, et al. Safety and pharmacokinetics (PK) of single rising oral doses of a novel HIV integrase inhibitor in healthy volunteers Presentation number A1-1725. Poster presented at 41st Interscience Conference of Ant imicrobial Agents and Chemotherapy (ICAAC); 17-20 September 2011; Chicago, IL
87. Sax PE,Wohl D,Yin MT,et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate coformulated with elvitegravir cobicistat , and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015 385 9987) 2606-15
88. Rockstroh JK, Lennox JL, Dejesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-nave human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011;53(8): 807-16
89. Minami R, Yamamoto M, Takahama S, et al. Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir. J Infect Chemother 2011;17 (2):183-8
90. Pe-rez-Matute P, Pe-rez-Martinez L, Blanco JR, Oteo JA. Neutral actions of raltegravir on adipogenesis, glucose metabolism and lipolysis in 3T3-L1 adipocytes. Curr HIV Res 2011; 9(3):174-9
91. De Castro N, Braun J, Charreau I, et al. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. Clin Infect Dis 2009;49: 1259-67